MicroHand S Laparoscopic Surgical Robot

MicroHand S stands as a landmark product in Chinese medical device development—the first domestically-manufactured laparoscopic surgical robot to achieve NMPA approval. Developed by Shandong WEGO Surgery Robot Co., Ltd. after more than a decade of research, the system combines multi-arm robotic precision with advanced 3D visualization and has established itself as a leader in 5G-enabled telesurgery applications.

Product Overview

The MicroHand S employs a master-slave architecture common to modern surgical robots, enabling surgeons to control robotic arms with enhanced precision while seated at an ergonomic console. Designed specifically for minimally invasive laparoscopic procedures, the system translates the surgeon’s hand movements into precise instrument motions within the patient’s body cavity.

WEGO developed the system with fully independent intellectual property rights, holding over 60 national invention patents. Core technologies span mechanical design, real-time control algorithms, stereoscopic visualization, and system integration—areas previously dominated by imported systems.

Key Features

MicroHand S is China’s first NMPA-approved domestic laparoscopic surgical robot, with 7-DOF arms, 540° end-effector rotation, and demonstrated 5G telesurgery across 3,000+ km distances.

• Seven Degrees of Freedom: Each robotic arm provides full spatial manipulation capability, matching or exceeding human wrist dexterity
• 540° End-Effector Rotation: Instruments rotate beyond natural hand capability, enabling complex suturing and knotting in confined spaces
• 3D Stereoscopic Visualization: Dual CMOS sensor camera system delivers high-resolution depth perception to the surgeon console
• Master-Slave Control: Real-time translation of surgeon movements to instrument tips with motion scaling for micro-precision
• 5G Telesurgery Ready: Optimized control architecture supports stable operation across long-distance network connections
• Modular Arm Design: Reconfigurable layout adapts to various surgical approaches and patient anatomies

Technical Specifications

WEGO’s MicroHand S fields three 7-DOF instrument arms plus one camera arm, with 10–12 mm trocars and master-slave control tolerating under 200 ms round-trip 5G latency.

Clinical Applications

MicroHand S received initial NMPA approval for general surgery procedures:

Approved Indications:

• Cholecystectomy (gallbladder removal)
• Inguinal hernia repair
• Hiatal hernia repair with fundoplication
• Hepatic cyst fenestration
• Appendectomy
• Sleeve gastrectomy (bariatric surgery)

Expanded Clinical Applications: Clinical experience has extended to urology (robot-assisted partial nephrectomy) and gynecology, with registration trials completed for these additional specialties. Published data from 5G-enabled remote partial nephrectomies demonstrated median operative times of 67 minutes with no major complications.

Clinical Evidence

The MicroHand S underwent extensive clinical validation before and after regulatory approval:

Pre-Approval Trials:

• 2014-2019: 103 cases at Xiangya Third Hospital of Central South University
• 2019-2020: 168 registration trial cases across two centers

Comparative Studies: Propensity score-matched analysis comparing MicroHand S to da Vinci for total mesorectal excision demonstrated:

• Comparable operative times between systems
• Similar oncological outcomes
• Lower total hospital and surgery costs with MicroHand S
• Longer installation time for MicroHand S

Telesurgery Experience: The system has completed more documented remote surgeries than any other platform globally. A 2023 series of 5G-enabled remote partial nephrectomies showed:

• 87% of patients at clinical T1 stage
• Median total network delay of 167 ms
• 100% procedural completion without conversion
• No major intraoperative or postoperative complications

Regulatory Status

The October 2021 NMPA approval made MicroHand S the first domestically-developed laparoscopic surgical robot cleared for commercial use in China, preceding approvals for competing domestic systems from MicroPort MedBot (January 2022) and other manufacturers.

Competitive Positioning

MicroHand S enters the Chinese market at approximately half the price point of the da Vinci system—estimated at around RMB 12.5 million versus RMB 25 million. This pricing strategy targets secondary and tertiary hospitals that previously lacked access to robotic surgery due to capital constraints.

The system’s 5G telesurgery capability represents a unique differentiator, with demonstrated clinical success in procedures spanning over 3,000 kilometers between surgeon and patient locations. This positions MicroHand S for applications in extending specialized surgical care to underserved regions.

Awards & Recognition

• Red Dot Design Award (2022)
• DFA Design for Asia Awards 2022 Merit Award

Frequently Asked Questions

What is the price of MicroHand S compared to da Vinci?

MicroHand S is priced at approximately half the cost of the da Vinci system in China—around RMB 12.5 million compared to RMB 25 million. Consumable and per-procedure costs also differ between the systems.

Can MicroHand S perform remote surgery?

Yes, MicroHand S has demonstrated extensive 5G telesurgery capability, completing procedures across distances exceeding 3,000 kilometers. The system maintains stable operation with network round-trip delays under 200 milliseconds.

What specialties can use MicroHand S?

Initial approval covers general surgery procedures. Clinical applications have expanded to urology and gynecology, with registration trials supporting additional indications beyond the original approval.

How does MicroHand S accuracy compare to other systems?

Published comparative data shows similar surgical outcomes to the da Vinci system. The seven-degree-of-freedom arms and 540° instrument rotation provide precision comparable to established platforms.